The early and accurate detection of prostate cancer is important to ensure timely management and appropriate individualized treatment. Currently, conventional imaging has limitations particularly in the early detection of metastases and at prostate-specific antigen (PSA) levels < 2.0 ng/mL. Furthermore, disease management such as salvage radiotherapy is best at low PSA levels. Thus, it is critical to capture the disease in the oligometastatic stage as disease progression and commencement of systemic therapies can be delayed by metastasis-directed therapy. Prostate-specific membrane antigen (PSMA) is overexpressed in prostatic cancer cells. Novel imaging modalities using radiolabeled tracers with PSMA such as 68 Ga-PSMA-positron emission tomography (PET)/computed tomography (CT) have shown promising results. We review the literature regarding 68 Ga-PSMA-PET/CT in the setting of primary prostate cancer and biochemical recurrence. At present, the best utilization of 68 Ga-PSMA-PET/CT appears to be in biochemical recurrence. 68 Ga-PSMA-PET/CT has high diagnostic accuracy for lymph node metastases and has been shown to have superior detection rates to conventional imaging, especially at low PSA levels. Ga-PSMA-PET/CT has been shown to have considerable clinical value and to impact treatment selection for patients with prostate cancer. Still in its infancy, the results of future clinical trials will be excitedly awaited.
Introduction
Radiological diagnostics are critical in the evaluation of patients with suspected metastatic or biochemically recurrent prostate cancer (PCa). 1, 2 The identification and localization of metastatic disease may significantly alter treatment options available to the patient. Moreover, the importance of expeditious identification of metastatic spread is increasing being recognized, specifically, at the oligometastatic setting. 3 Multiple groups have now demonstrated oncological benefit of salvage lymph node dissection (LND) or radiotherapy in the setting of low-burden metastatic disease. 4, 5 Furthermore, in the setting of isolated metastatic deposits, stereotactic radiotherapy or metastasectomy to distant metastases may provide benefit. These findings are corroborated by a recent systematic review and meta-analysis. 4 Specifically, Ost et al 6 have demonstrated an improved progression-free survival for oligometastatic PCa recurrence for patients treated with high-dose stereotactic body radiotherapy (3-year progression-free survival 99% vs. 79% with low dose). Traditionally, serial Prostate-specific membrane antigen (PSMA), computed tomography (CT), and bone scan have represented the mainstay of disease staging in advanced PCa. 1, 2, 7, 8 Diagnostic limitations to CT and bone scan imaging approaches have prompted the use of positron emission tomography (PET) in staging for advanced PCa. Early PET/CT scans utilized either choline-or flourodeoxyglucose-based tracers. While the early results were promising, these probes have a limited capabilitydparticularly during the early stages of metastatic spread or biochemical recurrence (BCR). 9 Thus, there is a need for an imaging modality that can detect metastatic disease progression at an earlier stage. PSMA is a transmembrane protein that is expressed at the cell surface of prostatic cells. 10 PSMA is an ideal target in PCa, because its expression increases with increasing cellular dysplasia. Numerous antibodies to PSMA have been developed; some of which have been radiolabeled to facilitate nuclear imaging. More recently, small molecules that bind with high affinity to PSMA have been developed. Initially reported in 2012, the most widely studied type of PSMA based PET/CT is 68 Ga-labeled on the small molecular inhibitor PSMA-11 (also known as PSMA HBED-CC). 11 We aim to provide a comprehensive review of the current state of 68 Ga-PSMA-PET/CT in advanced PCa.
PSMA
PSMA is a 750-amino-acid, 100-kDa, type II transmembrane glycoprotein. It consists of an 18-amino-acid intracellular domain, a 25-amino-acid transmembrane region, and a 707-amino-acid extracellular portion. 12 The gene for PSMA (FOLH1) has been located on the short arm of chromosome 11 (11p11.2) 13 and other genes from this same portion have also been associated with PCa. 14 PSMA is highly specific for the prostatic tissue and has a limited extraprostatic expression. Nevertheless, PSMA may be expressed in some tissues including neural tissue, salivary glands, neuroendocrine tissue, small bowel, and kidney. 15 However, prostatic expression has shown to be 12 times greater than that of the next highest organ. 16 Within the prostate, PSMA is expressed on the epithelium surrounding the prostatic ducts, on the apical region of the prostatic cells. 17 Dysplastic changes of the prostate results in the expression of PSMA on the surface of the prostatic ducts. 18 Indeed, PSMA expression is increased significantly in both prostatic adenocarcinoma tissue and lymph node metastases (LNMs) and is lowest in benign prostatic tissue. 19 Indeed, PSMA expression is 100e1000-fold higher in PCa cell membranes when compared to normal cells. 15, 20 Furthermore, increasing stage and grade of PCa results in increased cell membrane PSMA expression. 15, 20 The eventual progression to advanced PCa and castration resistance corresponds with further increases in expression of PSMA. 21 Sweat et al 19 demonstrated that only 2% of LNMs were negative for PSMA expression. Furthermore, Mannweiler et al 22 found~5% of primary tumors and 15% of metastases (mostly skeletal) were PSMA negative. PSMA has also been found to be expressed in bladder cancer and renal cell carcinoma, however it has a specificity of 94.5% for PCa compared with any other type of malignancy. 23, 24 As such, PSMA represents a promising target for imaging of PCa.
Small molecules similar in structure to peptides that bind with affinity to PSMA with subsequent cell internalization have been developed. PSMA-11 labeled to 68 Ga, a generator produced positron emitter, via the HBED chelator ( 68 Ga-PSMA HBED-CC or 68 Ga-PSMA-11) has been the most extensively studied in radiological diagnostics in advanced PCa. 11 3.
68
Ga-PSMA-PET/CT in BCR staging
A vast majority of evidence supporting the use of 68 Ga-PSMA-PET/CT is reported in the setting of BCR. 25 In a recent meta-analysis, 25 a positive finding was detected in 76% of patients with BCR undergoing 68
Ga-PSMA-PET/CT. Indeed, this meta-analysis highlights that pre-PET PSA predicts the positivity rate of 68 Ga-PSMA-PET/CT in the setting of BCR. Specifically, on pooled analysis, positivity rates for PSA 0e0.19 ng/mL, 0.2e1.0 ng/mL, 1.0e1.99 ng/ mL, and > 2.0 ng/mL were 42%, 58%, 76%, and 95%, respectively. Indeed, current data suggest that one of the advantages of 68 Ga-PSMA-PET/CT is the detection rate at low PSA levels in the setting of BCR. A metaregression performed in the same meta-analysis demonstrated that a PSA of 1.0 ng/mL was associated with a 70% risk of positive 68 Ga-PSMA-PET/CT. Similar findings were observed in a recent study by Meredith et al. 26 In their large cohort of 425 patients with BCR after radical prostatectomy (RP), a detection rate of 53.3% was observed for PSA levels from 0.5 ng/mL to 1 ng/mL and 79.1% for 1 ng/mL to < 2 ng/mL. PET/CT, it must be noted that the inclusion criteria for the respective choline-based meta-analysis has not been clearly reported. Specifically, it is not clear whether biopsy and resulting histopathological correlation was clinical performed on clinical discretion. As discussed, the inclusion of such series unduly inflates sensitivity and specificity profiles.
68 Ga-PSMA-PET CT in primary staging of high-risk PCa
The use of 68 Ga-PSMA-PET/CT in the primary staging of highrisk PCa is increasingly being reported. 33 Ga-PSMA-PET/CT, there was no significant difference on a per-patient level.
While there is improved clarity in the role of 68 Ga-PSMA-PET/CT in BCR, the role in primary staging is yet to be definitively determined. The benefit of 68 Ga-PSMA-PET/CT in primary staging in this setting appears to be identifying metastatic disease earlier and in uncommon locations, such as the mesorectum. 37 The identification of such disease may considerably alter the treatment algorithms for a given patient. No doubt, higher-volume prospective series with oncological outcomes are required. A phase III randomized controlled trial comparing 68 Ga-PSMA-PET/CT to conventional imaging is currently being undertaken in Australia (ProPSMA study, Australian New Zealand Clinical Trials Registry 12617000005358).
68
Ga-PSMA-PET in staging of intraprostatic disease
Multiparametric MRI (mpMRI) represents a promising imaging modality in the diagnosis of primary PCa.
38 68 Ga-PSMA-PET/CT in combination with CT and mpMRI has increasingly been utilized in experimental protocols to diagnose and localize intraprostatic PCa. 39e41 Fendler et al 39 studied the value of 68 Ga-PSMA-PET/CT in localization of primary tumor lesions. 68 Ga-PSMA-PET/CT was performed shortly before RP was correlated with histopathological six-segment prostate specimens. On a per-segment analysis,
Ga-PSMA-PET/CT had a sensitivity and specificity of 67% and 92%, respectively. However, of the 21 patients, two (10%) were 68 Ga-PSMA-PET/CT negative. The sensitivity for detection of seminal vesicle invasion was 73%, with a specificity of 100%. Ga-PSMA-PET/CT-directed radiotherapy. Of the cohort, there was 100% local control after 12 months, which delayed the commencement of androgen deprivation therapy or other systemic therapies. In the context of patients under consideration of salvage radiotherapy to the prostate bed, early treatment before significant PSA rises (as low as < 0.20 ng/mL) is associated with improved clinical outcomes. 53 Thus, due to low sensitivity at these levels, 68 Ga-PSMA-PET/CT needs further investigation and possibly combination with other imaging modalities before it can be routinely recommended to screen patients for adjuvant or salvage radiotherapy.
Conclusions
Current evidence points towards a role for 68 Ga-PSMA-PET/CT in the setting of BCR. The superiority of 68 Ga-PSMA-PET/CT compared to current imaging modalities seems to be most marked at low PSA levels. Detecting PCa recurrence expeditiously is critical as metastases are more likely to be locally confined or oligometastatic at this point. Metastasis-directed therapies, both lymphadenectomy and radiotherapy, are of use in this setting. Additionally, recent updated analysis from the CHAARTED trial have also shown the value of differentiating high-or low-volume disease. 54 With a minority of studies focusing on 68 Ga-PSMA-PET/CT in primary PCa, there is less evidence for its use in this setting as the true sensitivity for the detection of LNMs is not clear. Nevertheless, the majority of results so far were from retrospective case series. Studies validating imaging findings with histopathology are required as well as analysis of longer-term outcomes of 68 Ga-PSMA-PET/CT-directed therapy.
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